SCHEMBL402069

SCHEMBL402069

Cc1cc(Nc2cncc(CN3C[C@@H]4C[C@H]3CN4C(=O)c3cccc(C(F)(F)F)c3Cl)n2)n[nH]1

nearest known ligand 0.43

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
AURKA O14965 7/20 0.43
AURKB Q96GD4 5/20 0.43
P2RX7 Q99572 12/20 0.42
CTSS P25774 1/20 0.42
CTSK P43235 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL399614 0.90 AURKA (0.47) AURKAAURKB
SCHEMBL399206 0.90 AURKA (0.40) AURKAAURKBP2RX7CTSSCTSK
SCHEMBL401151 0.85 AURKA (0.45) AURKAAURKB
SCHEMBL403361 0.85 AURKA (0.45) AURKAAURKB
SCHEMBL398924 0.85 AURKA (0.45) AURKAAURKB
SCHEMBL3535817 0.80 AURKA (0.51) AURKAAURKB
SCHEMBL3529733 0.79 AURKA (0.40) AURKAAURKBP2RX7
SCHEMBL3526082 0.79 AURKA (0.40) AURKAAURKBP2RX7
SCHEMBL401815 0.78 AURKA (0.46) AURKAAURKBP2RX7
Trifluoroacetic Acid SCHEMBL15225961 0.78 AURKA (0.34) AURKAAURKBP2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2017279-B1 AMINOPYRIMIDINE DERIVATIVES HAVING AURORA-A-SELECTIVE INHIBITORY ACTIVITY MSD KK (JP) 2013-09-04 EP disclosed
US-8101621-B2 Aminopyridine derivatives having aurora a selective inhibitory action MSD K.K. (JP) 2012-01-24 US disclosed
US-20090192174-A1 Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-07-30 US disclosed
EP-2017279-A1 NOVEL AMINOPYRIDINE DERIVATIVE HAVING AURORA-A-SELECTIVE INHIBITORY ACTIVITY BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-01-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192174-A1 Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action RB1, AURKA, AURKC AURKA 2/4885AURKB 4/4885P2RX7 3822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.